seekingalpha.com
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Champions Oncology, Inc.CSBRNASDAQ
Loading
Latest News
Loading news...
accessnewswire.com
Champions Oncology Reports Revenue of $16.6 Million
Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its third quarter of fiscal 2026, ended January 31, 2026. Third Quarter and Recent Highlights: Record study service revenue of $16.6 million, up approximately 32% year over year Total revenue of $16.6 million, compared to $17.0 million in the prior-year period Adjusted EBITDA of $574,000; GAAP loss from operations of approximately $276,000 The Company's third quarter reflected record service revenue driven by strong study execution and the conversion of previously booked work.
accessnewswire.com
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026
HACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the third quarter ended January 31, 2026, on Thursday, March 12, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
seekingalpha.com
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
gurufocus.com
Market Today: Ford axes Lightning, iRobot bankrupt, Nvidia-China chips
Stock News Ford pivots from full EV to hybrids and storage: Ford Motor (F) will discontinue the allâelectric Fâ150 Lightning and replace it with a plugâin
accessnewswire.com
Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million
We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / December 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its second quarter of fiscal 2026, ended October 31, 2025. Second Quarter and Recent Highlights: Total revenue increased 11% to $15 million Oncology services profit of $7.8 million; oncology services margin of 52% Net income of $237,000 Adjusted EBITDA of $843,000 First Half 2026 Highlights: Total revenue increased 5% to $29 million Oncology services profit of $13.8 million; oncology services margin of 47% Adjusted EBITDA of $962,000 Robert Brainin, CEO of Champions, commented, "Our recent results reinforced our confidence in the Company's ongoing return to growth, as we continued to make progress.
gurufocus.com
First Look: iRobot Bankruptcy, Netflix-WBD Fight, Tesla Robotaxi
Stock News iRobot enters Chapter 11: iRobot (IRBT) filed for Chapter 11 and agreed to be acquired by contract manufacturer Picea Robotics, saying operations and
feeds.benzinga.com
Dow Settles Lower But Records Weekly Gain: Investor Sentiment Declines, Greed Index Moves To 'Fear' Zone
U.S. stocks fell on Friday, with the S&P 500 dropping over 1% and the Dow gaining 1.1%. The Fear and Greed index moved to Fear zone at 42.2.
accessnewswire.com
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025
HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the second quarter ended October 31, 2025, on Monday, December 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
seekingalpha.com
Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2026 Earnings Call September 15, 2025 4:30 PM EDT Company Participants Robert Brainin - CEO & Director David Miller - Chief Financial Officer Conference Call Participants George Marema - Pareto Ventures Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2026 Earnings Call.
accessnewswire.com
CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million
This release contains a headline correction from the previous publication. Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2026, ended July 31, 2025.
accessnewswire.com
Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025
HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter ended July 31, 2025, on Monday, September 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
seekingalpha.com
Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript
Champions Oncology (NASDAQ:CSBR ) Q4 2025 Earnings Call July 23, 2025 4:30 PM ET Company Participants David Barry Miller - Chief Financial Officer Ronnie Morris - CEO & Director Conference Call Participants Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Operator Greetings. Welcome to the Champions Oncology Fourth Quarter Fiscal Year 2025 Earnings Call.
accessnewswire.com
Champions Oncology Reports Record Annual Revenue of $57 Million
Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2025. Fourth Quarter Financial Highlights: Total revenue of $12.3 million Adjusted EBITDA loss of $1.2 million New data licensing revenue of approximately $200,000 Operating cash flow of $6.4 million Fiscal Year 2025 Financial Highlights: Record annual revenue of $57 million, an increase of 14% year-over-year Net income of $4.6 million Adjusted EBITDA income of $7.1 million Data license revenue of $4.7 million Year-end cash balance of $9.8 million Ronnie Morris, CEO of Champions, commented, "This past year was pivotal for the Company, as we returned to growth and profitability, launched a high-margin data business and laid the foundation for long-term value creation".
accessnewswire.com
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025
HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter and year ended April 30, 2025, on Wednesday, July 23, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
accessnewswire.com
Champions Oncology Announces Appointment of New CEO
HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, today announced that its Board of Directors has appointed Rob Brainin as Chief Executive Officer and member of the Board of Directors, effective August 25, 2025. Rob, who has served on Champions' Board since 2021, will succeed Dr. Ronnie Morris, who has led the company as CEO since 2017.
accessnewswire.com
Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners.
seekingalpha.com
Champions Oncology: Biological IP Is The Real Asset - Not Preclinical Services
Champions Oncology is transitioning from a traditional CRO to also a high-margin data licensing platform, unlocking new revenue and margin potential. The market undervalues CSBR, not reflecting its evolving business model and scalable, defensible oncology data assets in its current valuation. CSBR's unique, clinically-annotated PDX dataset and early AI/data licensing deals offer significant future upside as the business scales.
accessnewswire.com
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.
seekingalpha.com
Champions Oncology, Inc. (CSBR) Q3 2025 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2025 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Maj Soueidan - GeoInvesting George Marema - Pareto Ventures Operator Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2025 Earnings Call [Operator Instructions].